Moreover, a matched PDO pair from a mutant p53 CRC patient, respectively chemo-sensitive and chemo-resistant upon CRC therapy, impressively showed that dual HSF1-HSP90 inhibition impairs CRC survival independent of therapy status. This evidence concerns the gene TP53 and colorectal carcinoma.